Insider Selling: LivaNova PLC (NASDAQ:LIVN) CEO Sells 1,000 Shares of Stock

LivaNova PLC (NASDAQ:LIVN) CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $73.58, for a total transaction of $73,580.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of LIVN stock traded up $0.52 during trading on Monday, hitting $72.48. 357,700 shares of the company were exchanged, compared to its average volume of 566,330. The company has a debt-to-equity ratio of 0.13, a current ratio of 0.87 and a quick ratio of 0.61. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 3.09 and a beta of 0.57. The business’s 50-day moving average is $72.68. LivaNova PLC has a twelve month low of $64.80 and a twelve month high of $131.54.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.11. The firm had revenue of $250.80 million during the quarter, compared to analysts’ expectations of $254.89 million. LivaNova had a negative net margin of 19.64% and a positive return on equity of 9.38%. The company’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.68 earnings per share. On average, equities analysts predict that LivaNova PLC will post 2.6 earnings per share for the current year.

LIVN has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective on shares of LivaNova in a research report on Tuesday, April 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $100.00 price objective on shares of LivaNova in a research note on Friday, April 5th. BidaskClub raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Wednesday, March 27th. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Thursday, May 2nd. Finally, ValuEngine cut shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $106.40.

Several large investors have recently added to or reduced their stakes in the company. Redmile Group LLC lifted its position in LivaNova by 13.1% during the 1st quarter. Redmile Group LLC now owns 582,687 shares of the company’s stock valued at $56,666,000 after purchasing an additional 67,700 shares during the period. Primecap Management Co. CA lifted its position in LivaNova by 144.2% during the 1st quarter. Primecap Management Co. CA now owns 191,000 shares of the company’s stock valued at $18,575,000 after purchasing an additional 112,800 shares during the period. Vaughan Nelson Investment Management L.P. increased its stake in shares of LivaNova by 5.4% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 413,892 shares of the company’s stock valued at $40,251,000 after acquiring an additional 21,275 shares during the last quarter. Citigroup Inc. increased its stake in shares of LivaNova by 13.4% in the 1st quarter. Citigroup Inc. now owns 19,296 shares of the company’s stock valued at $1,877,000 after acquiring an additional 2,284 shares during the last quarter. Finally, FIL Ltd increased its stake in shares of LivaNova by 30.5% in the 1st quarter. FIL Ltd now owns 396,366 shares of the company’s stock valued at $38,546,000 after acquiring an additional 92,682 shares during the last quarter. 84.37% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Featured Article: What is the float in trading stocks?

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.